Epigenetics Drugs and Diagnostic Technologies Market is Expected to Grow at a CAGR of 19.4% from 2012 – 2018

Epigenetics is a regulatory mechanism that controls the gene expression without altering the genetic sequence. Epigenetic change in gene expression originates from the modification in transcription mechanism. Key components involved in the process of epigenetic transcriptory regulation include DNA methylation, histone modifications, micro RNA’s and non-coding RNA’s. However, our report focuses majorly on two types of epigenetic control factors: DNA methylation and covalent modification in histone proteins around which the DNA helix is wrapped. Epigenetic drugs make it possible to reverse the aberrant gene expression which leads to various disease states. With the increase in aging population, rising incidence of oncology and non-oncology disorders, the demand for epigenetic diagnosis and drugs would also increase.

Request Sample for more Comprehensive Analysis @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=422

The research report on Epigenetics Drugs and Diagnostic Technologies market provides detailed analysis of the global market and helps in understanding the driving forces for the growth of these technologies. The report on epigenetics drugs and diagnostic technologies has been categorized based on the mechanism of action which includes DNMT inhibitors and HDAC inhibitors. The segment of the report also provides market and forecast of blockbuster drugs such as vorinostat, romidepsin, azacitidine and decitabine. Furthermore, the report on epigenetics is also categorized based on diagnostic technologies namely DNA Methylation and ChIP (Chromatin Immunoprecipitation) Technology. Market size estimates and forecasts for the period 2010 to 2018 has been given for each of the segment and its sub-segment, in terms of USD million, using 2010 as a base year. The epigenetics drugs and diagnostic technologies market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2012 to 2018.

Geographically, the epigenetics drugs and diagnostics technologies market has been segmented into four major regions: North America, Europe, Asia Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019, along with the CAGR (%) for the forecast period 2013 to 2019. The epigenetics drugs and diagnostics technologies market study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises a qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five forces analysis and market attractiveness analysis. The entire section of market overview plays an important role in understanding the market on a global level. Separately, executive summary has been provided in the report, gives a brief overview of the report in a very precise and concise manner.

Enquire for Discount @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=422

The epigenetics drugs and diagnostic technologies market report also provides a highlight of the competitive landscape of the market wherein the market share analysis of the leading players, in terms of percentage share in 2011 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares.

The report concludes with the profiles of the major players in epigenetics drugs and diagnostic technologies market. Market players are profiled based on attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits, product portfolio and recent developments. Key market player’s profiles in this report are Celenge, Eisai Pharmaceuticals, Pharmacyclics, Merck, 4SC AG, Acetylon Pharmaceuticals, Inc., Astex Pharmaceuticals Inc., CellCentric Ltd., Celleron Therapeutics Ltd., Chroma Therapeutics Ltd., Epigentek Group Inc., EnVivo Pharmaceuticals Inc., Epizyme, Inc. Illumina Inc., Merck & Company Inc., MDxHealth, Oncolys BioPharma Inc., Novartis International AG, Promega Corporation, Spectrum Pharmaceuticals, Syndax Pharmaceuticals, Inc. Topotarget A/S, Valirx Plc and others.

Request TOC of the Report for Complete Review @ https://www.transparencymarketresearch.com/report-toc/422

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.